The deal grants Venus Remedies the rights to develop, register, and commercialise MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, in India. Currently, there are no approved MBL inhibitors available in the country.
The deal grants Venus Remedies the rights to develop, register, and commercialise MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, in India. Currently, there are no approved MBL inhibitors available in the country.